Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, Inc. (NRIX), sold 6,816 shares at $20.67 ($141K) on 2024-07-30, disclosed to the SEC on 2024-07-30.
Open-market sale of $141k NRIX by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.67 | 3,408 | $70K | 50.0% |
| 2 | $20.67 | 3,408 | $70K | 50.0% |
| Total | $20.67 avg | 6,816 | $141K | 100% |
| Filing → |
| NRIX | SELL | 2026-08-05 | $109K | — | Filing → |
| NRIX | SELL | 2026-07-30 | $90K | — | Filing → |
| NRIX | SELL | 2026-06-25 | $108K | — | Filing → |